Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | DHODH | Q02127 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459886 | 1.00 | HTT (0.83) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL29742388 | 1.00 | HTT (0.83) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL3460628 | 1.00 | HTT (0.83) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL8160654 | 0.91 | HTT (0.70) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL5436807 | 0.91 | HTT (1.00) | HTTLMNAKMT2ATAS1R3TAS1R1 | |
| SCHEMBL2406255 | 0.91 | HTT (1.00) | HTTLMNAKMT2ATAS1R3TAS1R1 | |
| SCHEMBL7152540 | 0.90 | HTT (0.69) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL7152538 | 0.90 | HTT (0.69) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL6570868 | 0.89 | LMNA (0.69) | HTTLMNAKMT2APDE4APDE4B | |
| SCHEMBL19630401 | 0.88 | HTT (0.66) | HTTLMNAKMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782252-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | claimed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | claimed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | claimed |
| US-5914349-A | ANTICONVULSANTS, EPILEPSY AND COGNITIVE AGENTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-06-22 | — | — | US | claimed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | claimed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | claimed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | claimed |
| JP-58140054-A | — | — | None | — | — | JP | disclosed |
| CN-110799491-B | Process for preparing substituted 4-aminoindane derivatives | 拜耳公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113372568-B | Preparation method of neodymium-based or holmium-based chiral metal-organic porous crystalline material, prepared material and application thereof | 合肥工业大学 | 2022-07-22 | — | — | CN | disclosed |
| US-11180441-B2 | Method for preparing substituted 4-aminoindane derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113372568-A | Preparation method of neodymium-based or holmium-based chiral metal-organic porous crystalline material, prepared material and application thereof | 合肥工业大学 | 2021-09-10 | — | — | CN | disclosed |
| US-4511581-A | Fungicidal indanylbenzamide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-04-16 | — | — | US | disclosed |
| JP-S58140054-A | INDANYLBENZAMIDE DERIVATIVE, ITS PREPARATION AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | SUMITOMO CHEM CO LTD | 1983-08-19 | — | — | JP | disclosed |
| EP-0086111-A1 | A fungicidal indanylbenzamide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-17 | — | — | EP | disclosed |
| EP-0086111-A1 | A fungicidal indanylbenzamide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-17 | — | — | EP | disclosed |
| EP-0086111-A1 | A fungicidal indanylbenzamide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180441-B2 | Method for preparing substituted 4-aminoindane derivatives | CYP4F2, CYP4F3, CYP4F8 | HTT 1470/4885LMNA 1549/4885KMT2A 1714/4885 |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | HTT 1119/4885LMNA 851/4885KMT2A 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.